Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × icaritin × Clear all
NCT05594927 2024-08-07

BESTPOP

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Recruiting
261 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03236649 2023-02-08

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Terminated
89 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01972672 2021-01-27

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Beijing Shenogen Biomedical Co., Ltd

Phase 2 Completed
70 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡